Meeting Banner
Abstract #4064

Evaluation of MR accuracy in neoadjuvant chemotherapy response assessment in patients showing change of biomarker status

Jeon-Hor Chen 1,2 , Shadfar Bahri 1 , Rita S. Mehta 3 , Philip M. Carpenter 4 , and Min-Ying Su 1

1 Center for Functional Onco-Imaging, University of California, Irvine, California, United States, 2 Department of Radiology, Eda Hospital and I-Shou University, Kaohsiung, Taiwan, 3 Department of Medicine, University of California, Orange, California, United States, 4 Department of Pathology, University of California, Orange, California, United States

This study attempted to investigate if the change of biomarker status after adjuvant chemotherapy (NAC) will affect MR accuracy in evaluation of residual tumor size. 59 breast cancer patients who received NAC and had residual tumor size in MRI and pathology and pre- and post-NAC biomarker information were analyzed. Our study noted biomarker conversion following NAC did not impact accuracy of MRI in determining residual tumor size in Her-2 negative and PR positive breast cancer. In Her-2 positive cancer, when converted into Her-2 negative cancer, the MR-pathology tumor size difference was remarkably higher than Her-2 positive cancer without biomarker conversion.

This abstract and the presentation materials are available to members only; a login is required.

Join Here